Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy …
JM Hartinger, V Kratky, Z Hruskova, O Slanar… - Frontiers in …, 2022 - frontiersin.org
The specific B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) is effective in
terms of the treatment of various immune-mediated glomerulopathies. The administration of …
terms of the treatment of various immune-mediated glomerulopathies. The administration of …
Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications
A Bensalem, D Ternant - Clinical pharmacokinetics, 2020 - Springer
The pharmacokinetics of monoclonal antibodies is highly variable among patients. Several
factors of variability, referred to as covariates in pharmacokinetic modeling, are known to …
factors of variability, referred to as covariates in pharmacokinetic modeling, are known to …
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study
PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment
(TTNT) when compared with the watch and wait strategy for patients with low–tumor burden …
(TTNT) when compared with the watch and wait strategy for patients with low–tumor burden …
[HTML][HTML] Optimization of rituximab Therapy in Adult patients with PLA2R1-associated Membranous Nephropathy with Artificial Intelligence
Introduction Rituximab is a first-line treatment for membranous nephropathy. Nephrotic
syndrome limits rituximab exposure due to urinary drug loss. Rituximab underdosing (serum …
syndrome limits rituximab exposure due to urinary drug loss. Rituximab underdosing (serum …
Monitoring disease activity in antineutrophil antibody‐associated vasculitis
FG Scurt, V Hirschfeld, L Schubert… - Scandinavian …, 2023 - Wiley Online Library
Antineutrophil cytoplasm antibody (ANCA)–associated vasculitis (AAV) comprises a group of
multisystem disorders with alternating periods of relapse and remission. Beyond that, a …
multisystem disorders with alternating periods of relapse and remission. Beyond that, a …
Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: a French multicentre retrospective study in 116 …
T Machet, T Quéméneur, E Ledoult, R Mesbah… - Joint Bone Spine, 2023 - Elsevier
Objective To evaluate rituximab (RTX) resistance at 3 months (M3) of induction therapy in
antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Methods …
antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Methods …
Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides During …
N Khoudour, F Delestre, F Jabot‐Hanin… - Arthritis & …, 2023 - Wiley Online Library
Objective Interindividual variability in response to rituximab remains unexplored in
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides. Rituximab …
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides. Rituximab …
The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition
Abstract Background and Objectives Rituximab is an anti-CD20 monoclonal antibody
approved in several diseases, including chronic lymphocytic leukemia (CLL), diffuse large B …
approved in several diseases, including chronic lymphocytic leukemia (CLL), diffuse large B …
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients
Abstract Background and Objective Cetuximab, an anti-epidermal growth factor receptor
(EGFR) monoclonal immunoglobulin (Ig) G1 antibody, has been approved for the treatment …
(EGFR) monoclonal immunoglobulin (Ig) G1 antibody, has been approved for the treatment …
Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors
Immune-checkpoint inhibitor (ICI) therapy has dramatically changed the clinical landscape
for several cancers, and ICI use continues to expand across many cancer types. Low …
for several cancers, and ICI use continues to expand across many cancer types. Low …